health · family: the solution exists but nobody can afford it
protection invented,not delivered
RSV prevention now exists but most of the children who die from it live in countries that cannot access it
Problem statement
Respiratory syncytial virus causes 33 million lower respiratory tract infections, 3.2 million hospitalizations, and approximately 100,000 deaths per year in children under five — the majority of those deaths in low- and middle-income countries (by 2015 estimates, more than 99% of in-hospital deaths among infants under 6 months occurred in developing countries). By 2025, two licensed immunization products existed to prevent RSV disease in young infants: a long-acting monoclonal antibody given to infants from birth, just before or during the RSV season, and Abrysvo, a maternal vaccine given to pregnant women in the third trimester. To date the maternal vaccine has only been used in high- and middle-income countries. WHO's preferred product characteristics ask that a monoclonal antibody's price be "similar to other new vaccines for feasibility of use in LMIC settings" and acceptable to a Gavi investment case. WHO prequalified Abrysvo on 12 March 2025; prequalification is a prerequisite for Gavi financing, and the Gavi Board was to decide during 2025 whether to add the vaccine to its portfolio — meaning the low- and lower-middle-income countries where the risk of severe disease and death is highest are not yet reached by a vaccine that already exists.
Why this matters
Many RSV deaths in LMICs occur outside a health facility and are not routinely captured or recorded — children die before reaching care. By 2015 estimates there were 1.4 million hospital admissions and 27,300 in-hospital deaths among infants younger than 6 months, of which more than 99% occurred in developing countries. About half of all RSV deaths in children under five occur in infants under 6 months, the age group most amenable to maternal vaccination or birth-dose monoclonal antibody approaches. Licensed prevention products now exist; what remains is getting them to the countries where the risk of severe disease and death is highest — a question of access, economics, and delivery — making this a paradigm case of the implementation gap between HIC and LMIC global health.
What’s been tried and why it hasn’t worked
Palivizumab (approved by the US FDA in 1998, and for years the only licensed RSV monoclonal antibody) requires monthly injections during the RSV season; in part because of its high cost it is used in most countries only among very high-risk infants, as of late 2019 it was registered in no low-income country, and a 2013 Cochrane review concluded it might not be cost-effective in LMICs. Extended half-life monoclonal antibodies, which could protect an infant for an entire RSV season with a single dose, promised simpler delivery and lower cost; one is now licensed, and WHO's stated preference is a price "similar to other new vaccines." For maternal vaccination, WHO's product characteristics note that comparative analyses of maternal immunization and monoclonal antibodies — programmatic suitability, cost-effectiveness in LMICs, and the potential for complementary use — will be important for policy-making. WHO SAGE recommended both approaches in September 2024, but the pathway from recommendation to country-level use runs through national regulatory approval, WHO prequalification, a Gavi investment decision and procurement, and cold storage capacity — a cascade that adds time.
What would unlock progress
Three parallel tracks could accelerate access: (1) WHO prequalification, a prerequisite for Gavi financing and for purchase by UN agencies, which Abrysvo cleared in March 2025; (2) a monoclonal antibody priced, as WHO's preferred product characteristics ask, "similar to other new vaccines" and acceptable to a Gavi investment case; and (3) the Gavi Board's decision on including the maternal RSV vaccine in its portfolio, due during 2025. A student contribution could address the delivery optimization challenge: modeling which combination of maternal vaccination and infant mAb deployment maximizes RSV mortality reduction under realistic LMIC health system constraints.
Entry points for student teams
A team could build a decision-analytic model comparing three RSV prevention strategies in a representative LMIC setting (e.g., Kenya or Mozambique): maternal vaccination only, birth-dose monoclonal antibody only, and a combined approach — evaluating cost-effectiveness under varying assumptions about antenatal care coverage, birth-dose delivery rates, cold chain capacity, and product pricing. Published RSV hospitalization incidence and case-fatality data for Kenya and Mozambique (Stein et al. pool studies from both) could inform realistic assumptions. Alternatively, a team could analyze the thermal stability requirements for mAb delivery outside the cold chain, evaluating whether controlled-temperature-chain protocols (allowing limited time outside 2-8 degrees C) could extend reach in last-mile settings. Relevant disciplines: health economics, epidemiology, operations research, immunology.
Genes
Structural cousins: stuck the same way, in other fields
Sources
WHO, "WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease," 2021. WHO News, "WHO prequalifies first maternal respiratory syncytial virus vaccine," Mar 19, 2025. Stein RT et al., "Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis," Pediatric Pulmonology 52(4):556-569, 2017. go to source 1 ↗ go to source 2 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
- WHO's March 2025 release says two licensed products now exist and that the maternal vaccine has so far been used only in high- and middle-income countries — the question is no longer "does it work?" but "who gets access?"
- Structurally related to health-paediatric-cancer-formulation-lmic-gap (effective HIC solutions inaccessible in LMICs due to cost/formulation) and health-oxygen-concentrator-low-resource-failure (product designed for HIC infrastructure fails in LMIC deployment context).
- The access gap between first use in high- and middle-income countries and arrival in Gavi-supported countries represents preventable deaths that could be quantified — a powerful framing for student teams interested in health equity research.
Reconciliation 2026-09-30: Fact repair after reading the whole write-up against every source it names. All three were fetched on 2026-09-30. Read in full: the WHO preferred product characteristics document for RSV monoclonal antibodies (the PDF behind https://www.who.int/publications/i/item/9789240021853, 20 pages, © WHO 2021); the WHO news item of 19 March 2025 (https://www.who.int/news/item/19-03-2025-who-prequalifies-first-maternal-respiratory-syncytial-virus-vaccine); and Stein et al. 2017 (full text from Europe PMC, PMC5396299, https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5396299/fullTextXML). (1) The long title said 97% of the children who die of RSV live in countries that cannot access prevention, and the text said 97–99% of deaths are in low- and middle-income countries. No source gives either figure. The news item says "the majority of paediatric RSV deaths occur in low- and middle-income countries"; the WHO document says that of the 2015 estimate of 1.4 million hospital admissions and 27 300 in-hospital deaths among infants under 6 months, more than 99% occurred in developing countries; Stein et al. say "the vast majority" of RSV deaths occur in developing countries. The title now says "Most" instead of "97%", and the sentence now gives the majority statement with the WHO document's in-hospital figure. (2) Removed because no source contains them: the 80% reduction in ICU admissions for nirsevimab, the 82% efficacy of Abrysvo in the first 90 days, the France and Spain rollout to 80% of newborns with a 70–90% fall in hospitalizations (also in the working notes above, now replaced by what the news item says), the ~$445 per dose US price, the ~$5 per dose Gavi price point, the 2027 projection for Gavi access (also in the working notes, now without the dates; the closing clause of the Problem Statement now says the low- and lower-middle-income countries where risk is highest are not yet reached by a vaccine that exists, which is what the news item says), the ~$1,500 per dose palivizumab price, the claim that monoclonal antibodies are inherently costlier to make than vaccines, the antenatal-care and "takes years" delivery claims about maternal vaccines, "healthcare worker training" and "years of delay" in the implementation cascade, the multi-dose vial of Abrysvo with Gates Foundation support by 2026, and the Medicines Patent Pool listing of clesrovimab. The product name nirsevimab appears in no source's text, only in the title of a 2020 trial report cited in the WHO document's reference list, and it went out with these claims; the entry point now says "birth-dose monoclonal antibody" and the sources' own description ("a long-acting monoclonal antibody administered to infants from birth") is used instead. In their place the text now carries what the sources say: two licensed products as of March 2025, the maternal vaccine so far used only in high- and middle-income countries, WHO's price preference for a monoclonal antibody ("similar to other new vaccines for feasibility of use in LMIC settings" and acceptable to a Gavi investment case), prequalification as a prerequisite for Gavi financing, and the Gavi Board decision due during 2025. (3) "More than two-thirds of RSV deaths in LMICs occur outside a health facility" is not in Stein et al., who say "many" such deaths occur outside a health facility and "a high percentage" outside the hospital setting; the sentence now says many. (4) "88% of RSV hospital admissions occur in LMICs" is in no source and was replaced by the WHO document's 2015 figures for infants under 6 months. (5) "Nearly half of all RSV hospitalizations and deaths affect infants under 6 months": the news item says about half of the deaths, and says nothing about hospitalizations; the sentence now says deaths only. (6) "The remaining barrier is purely access, economics, and delivery" is stronger than any source; the sentence now says licensed products exist and what remains is getting them to the countries where risk is highest. (7) Palivizumab: "the first RSV monoclonal antibody" became "for years the only licensed RSV monoclonal antibody," which is what the WHO document says; the sentence now carries the document's statements on monthly dosing, restricted use in part due to high cost, registration in no low-income country as of late 2019, and the 2013 Cochrane finding. (8) The three tracks in "What Would Unlock Progress" now name the levers the sources describe (prequalification, a price acceptable to a Gavi investment case, the Gavi Board decision) rather than the two unsourced ones. (9) The entry point's "cost-of-delivery data from Kenya, Ghana, and Mozambique" is not in any source; it now points to the incidence and case-fatality data for Kenya and Mozambique pooled in Stein et al. Confirmed in the sources and left as written: 33 million RSV lower respiratory infections (WHO document: 33.1 million in 2015), 3.2 million hospitalizations (WHO document; the news item gives more than 3.6 million), about 100,000 deaths a year in children under five (news item), palivizumab approved in 1998 (WHO document), SAGE recommendations in September 2024 (news item), WHO prequalification in March 2025 (news item, 12 March), and the three citations on the Source line (the WHO document's title and 2021 date, the news item's title and date, and Stein et al. in Pediatric Pulmonology 52(4):556–569, 2017, matching the Europe PMC record). Where the WHO document says extended half-life antibodies "could protect" an infant for a season with one dose, the text says could, and where the news item says one such product is licensed, the text says one, not the first. A second reader went over these repairs on the same day, confirmed each passage in the three sources, and made the three wording adjustments noted here. Title changed: "RSV Prevention Now Exists but 97% of the Children Who Die from It Live in Countries That Cannot Access It" is now "RSV Prevention Now Exists but Most of the Children Who Die from It Live in Countries That Cannot Access It". Display title unchanged. Genome tags untouched.